Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

This is the third publication of a four-part study. The double-blind, placebo-controlled study (n=23) found that 10 µg of LSD (vs 5 µg) produced psychedelic (psychotropic) effects (even more so at 20 µg). The peak effects were at 2.5h and ended at 5 hours.

Abstract

“”Microdoses” of lysergic acid diethylamide (LSD) are used recreationally to enhance mood and cognition. Increasing interest has also been seen in developing LSD into a medication. Therefore, we performed a pharmacokinetic-pharmacodynamic study using very low doses of LSD. Single doses of LSD base (5, 10, and 20 µg) and placebo were administered in a double-blind, randomized, placebo-controlled crossover study in 23 healthy participants. Test days were separated by at least 5 days. Plasma levels of LSD and subjective effects were assessed up to 6 h after administration. Pharmacokinetic parameters were determined using compartmental modelling. Concentration-subjective effect relationships were described using pharmacokinetic-pharmacodynamic modelling. Mean (95% confidence interval) maximal LSD concentrations were 151 pg/mL (127-181), 279 pg/mL (243-320), and 500 pg/mL (413-607) after 5, 10, and 20 µg LSD administration, respectively. Maximal concentrations were reached after 1.1 h. The mean elimination half-life was 2.7 h (1.5-6.2). The 5 µg dose of LSD elicited no significant acute subjective effects. The 10 µg dose of LSD significantly increased ratings of “under the influence” and “good drug effect” compared with placebo. These effects began an average of 1.1 h after 10 µg LSD administration, peaked at 2.5 h, and ended at 5.1 h. The 20 µg dose of LSD significantly increased ratings of “under the influence,” “good drug effects,” and “bad drug effects.” LSD concentrations dose-proportionally increased at doses as low as 5-20 µg and decreased with a half-life of 3 h. The threshold dose of LSD base for psychotropic effects was 10 µg.”

Authors: Friederike Holze, Matthias E. Liechti, Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Eef L. Theunissen, Urs Duthaler, Amanda Feilding, Johannes G. Ramaekers & Kim P. C. Kuypers

Notes

The same subjects were also studied by Hutten et al. (2020a), Ramaekers et al. (2020), and Hutten et al. (2020b).

The study is supported in part by the Beckley Foundation.

Summary

1 | INTRODUCTION

Lysergic acid diethylamide (LSD) is a prototypical hallucinogen that is increasingly used in experimental research and for the treatment of psychiatric patients.

PD outcomes were collected, but PK parameters could not be derived. A mean plasma elimination halflife of 175 minutes was reported after intravenous administration (2 g/kg9). We recently reported the first comprehensive PK data for orally administered LSD. In this study, we used a novel oral LSD formulation with documented longterm stability (single dose units) and higher content uniformity than is currently being used in experimental studies in healthy subjects, clinical trials in patients, and compassionate use in Switzerland.

2.1 | Study design

We performed a doubleblind, placebocontrolled, crossover study with four experimental 12hour test sessions. Only the novel LSD and placebo data are presented because the sampling time was too short to provide full concentration time curves.

The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki. All subjects provided written consent before participating.

2.2 | Participants

Twentynine healthy participants were recruited from the University of Basel campus via online advertisement. Of these, 27 completed the study, 13 males and 14 females. We excluded all subjects with the following criteria: pregnancy, personal or family history of major psychiatric disorders, use of medications that may interfere with the study drug, chronic or acute physical illness, tobacco smoking, illicit drug use within the last 2 months, and illicit drug use during the study.

What is already known about this subject

There is very limited data on the human pharmacokinetics of LSD. The data presented here relate plasma concentrations of LSD with its effects in clinical studies and intoxications.

The participants were not allowed to drink xanthine-containing liquids after midnight before the study day, and did not regularly use medications that could potentially interact with the study drug. Five participants had previously used a hallucinogen, including LSD, one to four times during their lives.

2.3 | Study procedures

The study included a screening visit, psychiatric interview, four 12 hour experimental sessions and an endofstudy visit. The participants rested in hospital beds, could interact with the investigator, and listened to music via headphones.

2.4 | Study drug

LSD was administered as a single oral dose in a solution to be administered orally in 1 mL of 96% ethanol according to GMP. The LSD content was 96.2 0.3 g(n = 6) after production and the solution was stable for longer than the study period.

2.5.1 | Blood sampling

Blood samples were collected before and after LSD administration. The plasma was stored at -20°C for longterm storage.

2.5.2 | Analysis of LSD and metabolite concentrations

LSD, OHLSD, norLSD and isoLSD levels were analysed in human plasma by ultrahighperformance liquid chromatography tandem mass spectrometry (UHPLC – MS/MS).

A sample of 50 liters of plasma was extracted with 150 liters of acetonitrile that contained 0.1 ng/mL LSDd3 and 0.25 ng/mL OHLSDd10 of the internal standards (ISs). The sample was loaded on the analytical column using a third pump and a flow rate of 0.1 to 0.6 mL/min within the first 0.5 minutes.

The flow rate of the analytical column was linearly decreased from 0.5 to 0 mL/min in the first 0.5 minutes of each run, and the mobile phase B concentration was increased from 10% to 95% between 0.5 and 2.75 minutes to elute the three analytes.

The analytes were detected by MRM in the positive mode with the interface temperature set at 500°C. The pharmacokinetic data were quantified using MultiQuant 3.0.1 software.

2.5.3 | Subjective mood

Subjective effects were assessed using Visual Analog Scales before, 1.5, 2, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 9.5 and 11.5 hours after LSD administration.

pharmacokinetic‐pharmacodynamic modelling

All analyses were performed using Phoenix WinNonlin 6.4 (Certara, Princeton, NJ, USA). A onecompartment model with firstorder input, firstorder elimination, and no lag time was used to determine the pharmacokinetic parameters. The PK model was fitted and evaluated, and the predicted concentrations were then used as an input to the PD model. A sigmoid maximum effect (Emax) model was selected for all PD effects, and the relationship between estimated effectsite concentrations and LSD effects was best described by a sigmoid model.

2.7 | Statistical analyses

Comparisons of PK parameters between the solution and capsule were made using ttests. Associations between peak concentrations and peak effects across subjects were assessed using Pearson correlations.

3.1 | Pharmacokinetics

LSD and OHLSD concentrations could be quantified in all subjects and at all time points. There were no sex differences in the PK parameters, and no differences in the PK of LSD between tobacco smokers and nonsmokers.

pharmacokinetic‐pharmacodynamic modelling

LSD produced robust increases in “any drug effect” and “good drug effect” VAS ratings, as well as “ego dissolution” (Figure S3). The variability in intensity in subjective drug effects is illustrated in the “any drug effect,””good drug effect” and “bad drug effect” curves, respectively.

LSD had EC50 values of 1.1 0.4 ng/mL and Emax values of 1.0 0.5 ng/mL for “any drug effect”, “good drug effect”, and “ego dissolution”, respectively.

The Cmax of LSD did not correlate with the subjective effects of LSD across subjects after the use of the same dose in all participants.

3.3 | Pharmacokinetic and pharmacokinetic‐pharmacodynamic comparison with LSD capsules

The modelpredicted geometric mean (CV%, 95% confidence interval [CI]) Cmax of the LSD solution was higher compared with the LSD capsule, and the modelpredicted LSD AUC values were higher compared with the LSD capsule. Additional analyses were performed to explore differences in absorption between the two formulations. The onset time needed to reach a minimum plasma LSD concentration of 0.3 ng/mL was significantly shorter and also less variable after administration of the solution compared with the capsule.

The PK of the two formulations were similar, with the exception that the EC50 value for “any drug effect” was lower for the capsule compared with the solution.

4 | DISCUSSION

The present study characterized the PK and subjective effects of a novel LSD solution that is intended for clinical research and use. The results are generally similar to those in previous studies, with the exception of higher Cmax and AUC values.

We expected a faster onset of action and more rapid absorption with the oral solution compared with the capsules, but the absorption coefficients and tmax values were not significantly different between the two formulations. Additionally, a threshold plasma LSD level was reached significantly faster with the solution.

The terminal t1/2 value of LSD should not depend on the type of formulation that is used.

The average AUC value for LSD was 13.3 and 8.1 ngh/mL in the present study and previous study, respectively. Although the oral drinking solution of LSD had higher oral bioavailability than the capsule formulation of LSD, the true LSD content of the previously used LSD capsules may have been lower than reported. Analytical tests on unused old LSD capsules performed years after study completion indicated a marked reduction of LSD content, suggesting that the actual LSD doses used were likely already lower than indicated during the studies.

Based on the results of different qualitycontrol measures, analytical findings, and clinical effects, we surmise that the previous studies actually used less LSD than reported. Although we cannot exclude possible differences in bioavailability, previous studies may have used lower doses of LSD than the present study, and the clinical response to 75 g of intravenous LSD was not significantly different from the oral 100 g dose.

In the present study, LSD produced high subjective “good drug effects” in almost all of the subjects, and low subjective “bad drug effects” in only a few subjects. The subjective LSD response was similar in intensity, onset and duration in both the novel LSD solution and the previously used capsule formulation.

The present study confirmed the previous finding11 that LSD concentrations do not predict the effects of LSD over time within each subject, but rather there is a close relationship over time withinsubjects.

The present study has limitations, such as using data from different studies that included different subjects, and it was not able to characterize the absorption and early distribution phase of LSD. However, it has notable strengths, such as including both male and female subjects and providing quality assurance data.

Study details

Compounds studied
LSD

Topics studied
Microdosing Neuroscience

Study characteristics
Placebo-Controlled Double-Blind Randomized

Participants
23 Humans

Authors

Authors associated with this publication with profiles on Blossom

Natasha Mason
Natasha Mason is interested in elucidating the neurobiological and cognitive mechanisms of (psychedelic) drugs by utilizing multimodal study designs, with a particular focus on substances that may hold therapeutic value.

Matthias Liechti
Matthias Emanuel Liechti is the research group leader at the Liechti Lab at the University of Basel.

Amanda Feilding
Amanda is the Founder and Director of the Beckley Foundation. She's called the 'hidden hand' behind the renaissance of psychedelic science, and her contribution to global drug policy reform has also been pivotal and widely acknowledged.

Johannes Ramaekers
Johannes Ramaekers is a professor at Maastricht University his work focuses on behavioral toxicology of drugs and combines methods from psychopharmacology, forensic toxicology and neuroscience to determine drug-induced changes in human performance. Some of this research is done with DMT.

Kim Kuypers
Kim Kuypers is a researcher at Maastricht University. Her work is concerned with understanding the neurobiology underlying flexible cognition, empathy, and well-being. One of the main ways she does is with the use of psychedelics.

Institutes

Institutes associated with this publication

Beckley Foundation
The Beckley Foundation is one of the leading voices that has spurred the scientific renaissance of psychedelics research. Led by Amanda Fielding, the NGO funds research and engages with politicians.

Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Compound Details

The psychedelics given at which dose and how many times

LSD 5 - 20
μg | 1x

Linked Research Papers

Notable research papers that build on or are influenced by this paper

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
This is the first of a four-part study (n=24) exploring the effects of a microdose of LSD (5-20 µg) on a range of measures, including mood, cognition, empathy, creativity, and physiological parameters. This part of the study found that LSD increased the pain tolerance of participants.

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers
This is the second publication of a four-part study. It was found that a microdose (20µg) of LSD increased neuroplasticity as measured by brain-derived neurotrophic factor (BDNF) levels at 6 hours (n=24). The results are, however, ambiguous and not present at all values/times.

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
This fourth publication on the administration of a microdose of LSD (5, 10, or 20 µg) found enhanced attention, slower information processing, more positive mood, and increased anxiety and confusion. Again, the results are small and quite ambiguous.

PDF of Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants